Login
$BRNX
$0.76 -$0.01 (1.63%) Close

Consolidated Balance Sheets

In millions of USD, except per-share amounts
Q4 FY2025
As of Dec 31, 2025
Q4 FY2024
As of Dec 31, 2024
Q4 FY2023
As of Dec 31, 2023
Q4 FY2022
As of Dec 31, 2022
Assets
CURRENT ASSETS:
Cash and cash equivalents
Trade receivables, net of allowance for credit losses of $380 as of December 31, 2023
Restricted deposits
Trade receivables, net of allowance for credit losses of $0 and $380 as of December 31, 2024 and 2023
Prepaid expenses and other receivables
Inventory
TOTAL CURRENT ASSETS
Restricted deposits
Operating lease right-of-use assets, net
Property, plant and equipment, net
Investment in joint venture
Other asset
TOTAL NON-CURRENT ASSETS
TOTAL ASSETS
CURRENT LIABILITIES:
Trade payables
Deferred revenue
Other payables
Current maturities of European Investment Bank (“EIB”) Loan
Current maturities of operating lease liabilities
TOTAL CURRENT LIABILITIES
NON-CURRENT LIABILITIES:
European Investment Bank (“EIB”) Loan
Share based payment liability
Warrants’ liability
Operating lease liabilities
TOTAL NON-CURRENT LIABILITIES
TOTAL LIABILITIES
SHAREHOLDERS’ EQUITY:
Ordinary Shares, no par value - Authorized 150,000,000 and 15,000,000 as of December 31, 2025 and December 31, 2024, respectively ; Issued and outstanding 715,852 and 231,280 as of December 31, 2025 December 31, 2024, respectively
Additional paid in capital
Foreign currency cumulative translation reserve
Accumulated deficit
TOTAL SHAREHOLDERS’ EQUITY
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support